Heterozygous Familial Hypercholesterolemia
The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’
In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events.
Monthly PCSK9 inhibitor shows ‘robust’ long-term LDL lowering for high-risk CVD
CHICAGO — For adults at high or very high CVD risk, a monthly PCSK9 inhibitor added to maximally tolerated oral lipid-lowering therapy maintained LDL reductions of more than 60% through 72 weeks, with no signals of attenuation.
Top-line data show durable LDL lowering with obicetrapib for adults with HeFH
Obicetrapib significantly reduced LDL vs. placebo in adults with heterozygous familial hypercholesterolemia and uncontrolled LDL, despite maximally tolerated therapy, according to the top-line results of the phase 3 BROOKLYN clinical trial.
Ace the Case #3: A 54-Year-Old South Asian Male with a History of Cardiac Percutaneous Intervention
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Ace the Case #2 - A 62-Year-Old Woman with Diabetes with an LDL-C of 53 mg/dL
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Ace the Case #1 – A 34-Year-Old Woman with Severe Heterozygous Familial Hypercholesterolemia (HeFH)
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Alirocumab approval now includes some pediatric patients with lipid disorder
Regeneron Pharmaceuticals announced the FDA extended its approval of alirocumab as an adjunct to diet and other LDL-lowering therapies to include patients aged 8 years and older with heterozygous familial hypercholesterolemia.
Top news of November: Semaglutide CV outcomes, treating statin intolerance and more
Healio and Cardiology Today have compiled a list of the most-read news in cardiology of November 2023.
Part of the Healio Network
Bempedoic Acid Topic Review
Bempedoic acid (Nexletol, Esperion Therapeutics) is a nonstatin low-density lipoprotein cholesterol (LDL-C)-lowering drug.
Early study suggests gene editing can lower LDL cholesterol via PCSK9 inhibition
PHILADELPHIA — A novel single-dose CRISPR base-editing infusion for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient, a speaker reported.